RESEARCH
KRAS Mutations Shape Immunosuppressive Tumor EnvironmentA review describes how KRAS mutations—present in approximately 52% of colorectal cancers—actively create an immunosuppressive tumor microenvironment, presenting a major barrier to both targeted therapy and immunotherapy. (Frontiers in Oncology)